On October 22, U.S. spot XRP exchange-traded funds (ETFs) recorded net inflows of $3.5464 million, with the Franklin XRP ETF (XRPZ) being the sole fund attracting new money. The cumulative net inflows for the XRP ETF group reached $1.804 billion, while the group's total net assets stood at $1.488 billion. The Franklin XRP ETF alone has amassed $519 million in cumulative net inflows. This inflow indicates continued investor interest in XRP-related funds, following a previous day when both Solana and XRP ETFs saw positive net inflows.
The U.S. spot XRP ETFs recorded $3.5464 million in daily net inflows, providing context for readers interested in cryptocurrency funds. For readers following the broader crypto market, 44 of 50 major cryptocurrencies on Pluang rose as of Oct 24, 2026 00:22 WIB. Notable movers include BNB at Rp13.493.881 with a 3.04% gain and YFI at Rp39.837.602 with a 3.00% gain.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
